UNSPSC 51203201: Mycophenolate mofetil

This classification denotes an inosine monophosphate dehydrogenase inhibitor and immunosuppressant, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9242ECW6R0. European Medicines Agency schedules Mycophenolate mofetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03360MIG. Mycophenolate mofetil generally arises in the molecular formula C23H31NO7. The term 'mycophenolate mofetil' is a United States Adopted Name designation.

Mycophenolate mofetil bears US NLM identifiers UMLS ID C0209368 and NCI Concept Code C1468. Most nations, for tariff and trade purposes, schedule mycophenolate mofetil under 29419000 and SITC 54139. SMILES: CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC.

UNSPSC 51203201 Mycophenolate mofetil is a Commodity code that does not align with recent state and local procurement activity in the source. The code nominally identifies a specific immunosuppressant pharmaceutical product, but the recent opportunities posted under this code cover naloxone procurement, emergency medical supplies for fire departments, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which involve mycophenolate mofetil or transplant immunosuppression. The source shows no recent solicitations for the actual product named by this Commodity code.

The issuing bodies posting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance with participation from Oregon and other members). Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon. The mismatch between the code's nominal scope and the actual goods being solicited—emergency pharmaceuticals, fire-rescue medical supplies, and generic drug programs rather than transplant-specific immunosuppressants—suggests either systematic miscoding in the posting jurisdictions or that this Commodity code is not the appropriate classification for current state and local pharmaceutical procurement. Business development professionals should verify code applicability with issuing bodies before pursuing opportunities listed under this designation, as the recent activity does not reflect mycophenolate mofetil demand or transplant-related pharmaceutical sourcing.